Dose-ranging activity of the newly registered antituberculosis drug bedaquiline (TMC207)

Expert Review of Anti-Infective Therapy

Volumn 11, Issue 7, 2013, Pages 649-651

  Grosset, Jacques H ^a,b   Ammerman, Nicole C ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

tuberculosis treatment

Indexed keywords

BEDAQUILINE; ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN;

BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; COLONY FORMING UNIT; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; HUMAN; LOADING DRUG DOSE; LUNG TUBERCULOSIS; OUTCOME ASSESSMENT; PATIENT SAFETY; REGISTER; REVIEW; SPUTUM CYTODIAGNOSIS;

EID: 84880865942     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2013.811848     Document Type: Review

References (14)

1. US FDA. Sirturo (bedaquiline) NDA 204384 Accelerated Approval Letter. (2012
2. Andries K, Verhasselt P, Guillemont J et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307(5707), 223-227 (2005
3. Cole ST, Alzari PM. Microbiology. TB -A new target, a new drug. Science 307(5707), 214-215 (2005
4. Koul A, Dendouga N, Vergauwen K et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat. Chem. Biol. 3(6), 323-324 (2007
5. Rustomjee R, Diacon AH, Allen J et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob. Agents Chemother. 52(8), 2831-2835 (2008
6. Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am. Rev. Respir. Dis. 121(6), 939-949 (1980
7. Donald PR, Sirgel FA, Venter A et al. Early bactericidal activity of antituberculosis agents. Expert Rev. Anti. Infect. Ther. 1(1), 141-155 (2003
8. Jindani A, Doré; CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am. J. Respir. Crit. Care Med. 167(10), 1348-1354 (2003
9. Diacon AH, Dawson R, Von Groote-Bidlingmaier F et al. Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis. Antimicrob. Agents Chemother. 57(5), 2199-2203 (2013
10. Diacon AH, Dawson R, von Groote-Bidlingmaier F et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: A randomised trial. Lancet 380(9846), 986-993 (2012
11. WHO. Multidrug-resistant tuberculosis (MDR-TB). 2013 Update (2013
12. Avorn J. Approval of a tuberculosis drug based on a paradoxical surrogate measure. JAMA 309(13), 1349-1350 (2013
13. Diacon AH, Donald PR, Pym A et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: Long-Term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob. Agents Chemother. 56(6), 3271-3276 (2012
14. Haxaire-Theeuwes M, Diacon AH et al.; The TMC207 Team. Phase 2 open-label trial of TMC207 in an MDR-TB treatment regimen. Presented at: 42nd Union World Conference on Lung Health. Lille, France, 26-30 October 2011